Clinical Trial Update: Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating concurrent chemoradiotherapy with or without metronomic capecitabine for high-risk nasopharyngeal carcinoma (T1-2N1M0).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Capecitabine (capecitabine)

Snippet

Sponsor: Chongqing University Cancer Hospital | Conditions: Nasopharyngeal Cancinoma (NPC) | Phase 3 | Status: ACTIVE_NOT_RECRUITING